Trial Profile
Multi-Center, Placebo-Controlled, Dose-Ranging Phase 2 Electrophysiological Study of Intranasal Administration of MSP-2017 for the Conversion of Induced Paroxysmal Supraventricular Tachycardia (PSVT) to Sinus Rhythm
Status:
Completed
Phase of Trial:
Phase II
Latest Information Update: 01 Jan 2021
Price :
$35
*
At a glance
- Drugs Etripamil (Primary)
- Indications Paroxysmal supraventricular tachycardia
- Focus Proof of concept; Therapeutic Use
- Acronyms NODE-1
- Sponsors Milestone Pharmaceuticals
- 31 Jul 2018 Results assessing efficacy and safety published in the Journal of the American College of Cardiology
- 11 May 2017 Primary endpoint (The percentage of subjects successfully converted to sinus rhythm within 15 minutes of study drug administration) has been met, according to a Milestone Pharmaceuticals media release.
- 11 May 2017 According to a Milestone Pharmaceuticals media release, results from this trial were presented at the Heart Rhythm 2017, the Heart Rhythm Society's 38th Annual Scientific Sessions.